Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40D1N | ISIN: US18978H3003 | Ticker-Symbol:
NASDAQ
21.01.25
21:54 Uhr
0,106 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CNS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CNS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur CNS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.01.CNS Pharmaceuticals, Inc. - 8-K, Current Report5
CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln
11.12.24CNS Pharmaceuticals, Inc. - 8-K, Current Report5
05.12.24CNS Pharmaceuticals sets date for virtual investor event2
05.12.24CNS Pharmaceuticals veranstaltet am 11. Dezember 2024 den "Virtual Analyst & Investor Day"228Live-Webcast-Diskussion mit international anerkannten Meinungsbildnern auf dem Gebiet von Glioblastoma Multiforme (GBM) Das Unternehmen widmet sich mit großem Engagement der aggressivsten...
► Artikel lesen
05.12.24CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024237Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival...
► Artikel lesen
03.12.24CNS Pharmaceuticals, Inc. - 8-K, Current Report-
25.11.24CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM After Failure of Standard First Line Therapy301Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half...
► Artikel lesen
18.11.24CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology160HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary...
► Artikel lesen
15.11.24CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results267Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond data...
► Artikel lesen
14.11.24CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report-
04.11.24CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment344Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc....
► Artikel lesen
01.11.24CNS Pharmaceuticals erhält Fristverlängerung für Nasdaq-Compliance3
01.11.24CNS Pharmaceuticals granted Nasdaq compliance extension1
01.11.24CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement241HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary...
► Artikel lesen
01.11.24CNS Pharmaceuticals, Inc. - 8-K, Current Report1
23.10.24CNS Pharmaceuticals secures $3 million in registered direct offering8
23.10.24CNS Pharmaceuticals sichert sich 3 Millionen US-Dollar durch registrierte Direktplatzierung2
23.10.24CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules348HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary...
► Artikel lesen
23.10.24CNS Pharmaceuticals droht Delisting von der NASDAQ aufgrund von Preisregel5
23.10.24CNS Pharmaceuticals faces NASDAQ delisting over price rule3
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,2